Literature DB >> 6139152

Somatostatin and dementia in Parkinson's disease.

J Epelbaum, M Ruberg, E Moyse, F Javoy-Agid, B Dubois, Y Agid.   

Abstract

The concentrations of somatostatin in the cortex, hippocampus and caudate nucleus of subjects with Parkinson's disease were determined by radioimmunoassay. Somatostatin levels in the frontal cortex were significantly reduced in Parkinsonian subjects who were slightly or severely demented compared to controls and to non-demented Parkinsonians. Significant reductions were also observed in the hippocampus and entorhinal cortex of severely demented subjects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6139152     DOI: 10.1016/0006-8993(83)90277-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  22 in total

1.  CSF somatostatin-like immunoreactivity in dementia of Parkinson's disease.

Authors:  W Poewe; T Benke; E Karamat; L Schelosky; M Wagner; G Sperk
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-12       Impact factor: 10.154

2.  Dementia in idiopathic Parkinson's disease. A neuropathological study of 32 cases.

Authors:  P Gaspar; F Gray
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

Review 3.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

4.  Cortical vasoactive intestinal peptide in relation to dementia in Parkinson's disease.

Authors:  S Jegou; F Javoy-Agid; C Delbende; M Ruberg; H Vaudry; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-08       Impact factor: 10.154

5.  Neuropeptide gene expression in brain is differentially regulated by midbrain dopamine neurons.

Authors:  N Lindefors; S Brené; M Herrera-Marschitz; H Persson
Journal:  Exp Brain Res       Date:  1990       Impact factor: 1.972

6.  Ventricular somatostatin-like immunoreactivity in patients with basal ganglia disease.

Authors:  H Cramer; A Wolf; K Rissler; K Weigel; C Ostertag
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

7.  Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.

Authors:  M Strittmatter; G F Hamann; D Strubel; H Cramer; K Schimrigk
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

8.  Reduced cerebral cortical but elevated striatal concentration of somatostatin-like immunoreactivity in dominantly inherited olivopontocerebellar atrophy.

Authors:  S J Kish; Y Robitaille; M el-Awar; L Schut; L DiStefano; M J Ball; M F Mazurek
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-09       Impact factor: 10.154

Review 9.  The hypothalamus in Parkinson disease.

Authors:  R Sandyk; R P Iacono; C R Bamford
Journal:  Ital J Neurol Sci       Date:  1987-06

Review 10.  Neuropeptides in dopamine-containing regions of the brain.

Authors:  A Albanese; M C Altavista
Journal:  Ital J Neurol Sci       Date:  1984-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.